Duan Qintong, Li Yufeng, Ou Lijia, Li Yajun, Zeng Ruolan, He Yizi, Pan Tao, Chen Siwei, Chen Huan, Zang Hui, Zhou Hui, Xiao Ling
Department of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
J Cancer. 2022 Mar 14;13(6):1785-1795. doi: 10.7150/jca.68453. eCollection 2022.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis of the literature on DLBCL treatment, and discussed cooperation among authors, countries, and institutions, and identified research hotspots for DLBCL treatment. We searched the Web of Science Core Collection (WOSCC) using "Diffuse Large B Cell Lymphoma or DLBCL" and "Treatment or Therapy or Clinical Trial" as the subject terms, and analyzed the publication year, research direction, country/region, institution, author, source publication, distribution of funding institutions, and other conditions provided by the database. In addition, scientometrics software was used to analyze literature citations and cooperative publications. Bibliometric analyses were performed using https://bibliometric.com/app and VOSviewer. Network maps were generated to evaluate collaborations between different authors, countries, institutions, and keywords. A total of 7,255 studies on treatment of DLBCL were retrieved from the WOSCC on February 19, 2021. We found that the number of publications increased gradually from 1999 to 2021, and this trend was relatively stable in the past 3 years. The countries that produced the most publications were the United States, China, and Japan. Among institutions, University of Texas MD Anderson Cancer Center published the most manuscripts. Furthermore, the United States also had the most annual publications, citations, distribution of journal sources, and funding. Cooperative research between countries is also relatively important to treatment of DLBCL. Therapeutic regimens such as CHOP and R-CHOP, and immunotherapy (CAR-T, PD1/PDL1, and CAR-NK, etc.), have received increased attention. Bibliometric analysis of studies related to DLBCL treatment can help researchers and clinical workers quickly understand the hotspots and development trends in this field, and provide reference for the formulation of public health policies.
Comput Biol Med. 2022-7
J Control Release. 2022-5
Front Endocrinol (Lausanne). 2022
Hum Vaccin Immunother. 2023-12-15
Aesthetic Plast Surg. 2022-12
Front Aging Neurosci. 2023-5-16
Front Immunol. 2022
Front Med (Lausanne). 2025-1-29
Blood Adv. 2024-7-23
J Hematol Oncol. 2020-12-14
Expert Opin Investig Drugs. 2021-1
N Engl J Med. 2020-2-6
Expert Opin Biol Ther. 2019-8-28
Nat Rev Clin Oncol. 2019-10